Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...
Clinical research conducted with participation from Florida Cancer Specialists & Research Institute, LLC (FCS) continues to ...
The company highlighted in its statement the recent start of the IDeate-Lung02 of B7-H3-directed antibody-drug conjugate ifinatamab deruxtecan (I-DXd) – part of a large-scale alliance with ...
which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and ...
which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and ...
The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's protocol amendment proposal to study anticancer drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback